

Innate **Immuno**therapeutics

(formerly Innate Therapeutics)



**A Phase 2 company treating Secondary
Progressive Multiple Sclerosis**

Forward Looking Statements

This Presentation (and any financial information that may be provided by the Company) may contain forward looking statements that involve risks and uncertainties. Such statements include statements regarding the Company's belief or current expectation and are necessarily based on the Company's current understanding of the markets and industries in which it operates. That understanding could change or could prove to be inconsistent with actual developments. The Company's actual results could differ materially from the results discussed in this Presentation, including those anticipated in or implied by any forward looking statements.



Investment Summary

- There are no drugs specifically approved to treat the chronic and disabling progressive form of Multiple Sclerosis – Innate has a promising drug currently in Phase 2A human trials in NZ.
- This unmet need translates into an annual market in excess of US\$3B.
- Existing results from pre-clinical models and compassionate human use (n=8) shows safety, tolerability and real benefits in 4 out of 8 patients.
- A successful Phase 2 trial program will return large multiples to investors through milestones + royalties and/or sale of the technology/company.

Key Management

Liz Hopkins, B.Sc. (Hons)

Pharmacology. Executive Director
Formerly Global Project
Manager, Pfizer Europe HQ

Simon Wilkinson, CEO

25 yrs finance, &
management including 10 yrs
in biotech

Peter Bradley, BAppSc, MMgt
(Tech). Chief BDO

25 yrs biotech experience

Gill Webster, Ph.D, Chief Scientific
Officer, research immunologist

Investment & Structure

- US\$40M raised in notes & shares
- NZ unlisted public since 2000
- Fully converted – 110M shares
- Value est. post 2A - US\$60-90M





Pipeline

Therapeutic Area	Indication	Partner	Discovery	Preclinical	Phase 1	Phase 2A Safety	Phase 2B PoP
Autoimmunity	Multiple Sclerosis	Not partnered					
Oncology	Refractory Prostate and Bladder Cancer (treatment vaccine adjuvant)	Not partnered					
Oncology	Early Stage Bladder Cancer	Not Partnered					
Vaccines	Peptide Vaccines (adjuvant)	Not Partnered					
Anti-Infectives	Hepatitis	Not Partnered					
Oncology	Radiation Therapy (co-therapy)	Not Partnered					
Biodefense	Radiation Protection	Not partnered					
Drug Delivery	Undisclosed	Not partnered					



Lead Candidate

1. MIS416 – lead drug candidate developed off the Company's immunomodulator microparticle platform.
2. GMP pilot scale manufacturing in place.
3. Currently in N.Z. Phase 1B/2A clinical development for **secondary progressive multiple sclerosis (SPMS)**.
4. Currently also in Japanese Phase 1B clinical development (as an adjuvant) **for a cancer treatment vaccine in refractory bladder and prostate cancer patients.**



Upcoming milestones:

- Q1/2012 – Phase 2A SPMS MS trial reports
- Q4/2012 – Phase 1B cancer adjuvant trial reports
- H2/2012 – Phase 2B SPMS study to commence



Clinical Information

- MIS416 comprises 2.0 x 0.5 micron sized rod shaped microparticles incorporating both TLR9 and NOD2 agonists.
- In the EAE animal model, repeat studies showed MIS416 delayed onset, incidence, & severity of disease, and enhanced recovery.
- In human cells and/or compassionate patient assays, MIS416:
 - upregulates anti-inflammatory mediators, including PGE2 & IL10
 - reduces serum levels of adhesion molecules including VCAM-1, ICAM-1, & E-selectin
 - upregulates soluble factors implicated in potential axonal protection and repair, including GM-CSF
- Current Phase 2A study comprises 4 dose escalation groups (n=3/cohort), and a six month dose confirmation phase (n=12) with patients treated weekly. Primary objectives are safety with any clinical improvements captured under secondary endpoints.





Commercial Strategy

- In 2007, the relapsing-remitting MS market was valued at US\$5.3b – forecast US\$9.8b by 2017.
- 50%+ of RRMS patients develop secondary progressive disease (SPMS). **There are no specifically approved drugs to treat SPMS.**
- MIS416 targets patients with SPMS. It may also be effective in RRMS.
- Four SPMS patients treated on compassionate grounds (non-controlled but clinician supervised) displayed sustained and significant improvements in clinical signs and symptoms associated with their disease condition.
- The current formal 2A trial is a precursor to a substantive proof of principle 2B study programmed to complete in mid 2014.
- Current big Pharma interest bodes well for a sale/licensing of the technology (with potentially wider applications than ‘just’ MS) post 2B.

Intellectual Property


‘Use’ patent applications in major markets include:

- **Multiple Sclerosis**
- **Oncology**
- **Anti-Infection**



Financial Snapshot

- Innate Therapeutics is New Zealand unlisted public company with financials (since 2000) prepared and audited in compliance with NZ GAAP / NZ IFRS.
- US\$40 million raised over multiple rounds (including rights issues, private placements and one public issue) since 2000.
- **Current Cash and undrawn grants:** US\$3 million (inc US\$550k provided by US MS Society & Merck Serono & US\$480k NZ Govt)
- **Operational burn rate:** US\$100,000 per month
- **Phase 2A cost to complete:** US\$800,000
- **Shares (or equivalent) on issue:** 101 million
- **Phase 2B est. cost:** US\$6 million
- **Next Round (Q2/2012):** US\$10 million
- **Valuation post round:** US\$85 million
- **Exit Target:** US\$500 million



Please Contact



Simon Wilkinson, CEO, +64 21 661 830 or
simon@innateimmuno.com

www.innateimmunotherapeutics.com